Paxlovid, authorized to treat high-risk people early in infection, didn’t meaningfully reduce illness in exposed adults
As fourth doses of Covid vaccines roll out, some are questioning whether the general population needs them. At the center of this debate are mysterious T-cells. WSJ’s Daniela Hernandez explains T-cells’ role in Covid immunity and how they relate to antibodies. Illustration: Laura KammermannThe Covid-19 pill from Pfizer Inc. failed to prevent symptomatic infections in adults who had been exposed to the pandemic virus, a late-stage study found.
Pfizer said Friday that the drug, named Paxlovid, failed the study’s main objective of meaningfully reducing the risk of confirmed and symptomatic
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more: